Prior to treatment with NEO-201, ten and six patients with colorectal cancer had received anti-VEGF and anti-EGFR directed therapy respectively, and one patient had previously received an immune checkpoint inhibitor (pembrolizumab). The gene discussed is VEGFA; the disease is colorectal cancer.